The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers
targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical …

Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

Purpose: Prostate specific membrane antigen-targeted positron emission tomography/
computerized tomography has the potential to improve the detection and localization of …

Prostate cancer is the most common cancer diagnosis in men in the United States and a
leading cause of cancer-related morbidity and mortality (1). It can exist along a wide …

Purpose The detection of lymph-node metastases (N1) with conventional imaging such as
magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for …

Purpose: To evaluate the performance of radiomic features (RF) derived from PSMA PET for
intraprostatic tumor discrimination and non-invasive characterization of Gleason score (GS) …

Background PSMA PET is a promising method for primary lymph node staging in prostate
cancer. However, recent systematic reviews have identified only a limited number of studies …

18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-
pentanedioic acid), a prostate-specific membrane antigen–targeting radiotracer, has shown …

Purpose: The advanced prostate cancer therapeutic landscape has changed dramatically in
the last several years, resulting in improved overall survival of patients with castration naïve …